Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 5

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 5
---
 of the immune modulating and
clinical activity of the combination at the inaugural AACR-IO congress in February of 2025 and additional data are anticipated in the impending months.

Beyond oncology, agenT-797 has shown promise in acute pulmonary immune failure. In a clinical trial (NCT04582201) evaluating patients with moderate to severe
viral acute respiratory distress syndrome (ARDS), agenT-797 was associated with overall survival exceeding 70%. In the subgroup of patients receiving veno-venous extracorporeal membrane oxygenation (VV ECMO), survival was 80%—compared to a
historical ICU control survival rate of approximately 10%. These results were published in Nature Communications in February 2024. Additional clinical and translational findings from this program were presented at the American Thoracic
Society (ATS) Annual Meetings in 2023 and 2024. We intend to advance development of agenT-797 for viral ARDS in a large-scale, externally funded platform trial.

In parallel, we are developing a pipeline of next-generation, engineered iNKT cell therapies designed to enhance tumor targeting, overcome resistance, and
remodel the tumor microenvironment. Our two most advanced preclinical candidates are MiNK-413, an IL-15 armored CAR-iNKT targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored CAR-iNKT targeting fibroblast activation protein
(FAP). Both programs have shown robust preclinical activity and competitive manufacturing advantages. MiNK-413 has demonstrated tumor clearance and improved persistence in preclinical models of hematologic malignancy. MiNK-215 has shown potent
activity in lung and colorectal cancer models, including organoid systems with liver metastases, where it enhanced T cell-mediated killing, depleted suppressive FAP-expressing stromal cells, and improved CD8+ infiltration. Preclinical data were
presented at the American Society of Gene and Cell Therapy (ASGCT) 2023 and American Association for Cancer Research (AACR) 2024 annual meetings. IND-enabling studies for MiNK-215 are underway.

To date, we have treated nearly 100 patients across cancer and immune-mediated indications. Our work has yielded insights into the mechanisms driving iNKT
cell activity, durability, and safety. With our vertically integrated platform, proprietary technologies, and experienced leadership team, we believe we are well positioned to deliver transformative cellular immunotherapies that can